NCT06667349View on ClinicalTrials.gov

TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk

PHASE4CompletedINTERVENTIONAL
Enrollment

1,727

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

March 3, 2024

Study Completion Date

June 16, 2024

Conditions
STEMI - ST Elevation Myocardial InfarctionStent ThrombosisAntiplatelet Agents
Interventions
DRUG

Ticagrelor

Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI

Trial Locations (1)

755000

National Institute of Cardiovascular Diseases, Karachi

All Listed Sponsors
lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER

NCT06667349 - TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk | Biotech Hunter | Biotech Hunter